Tardive dyskinesia in 2 patients treated with ziprasidone

Journal of Psychiatry and Neuroscience

Volumn 29, Issue 6, 2004, Pages 467-469

  Ananth, Jambur ^a,b   Burgoyne, Karl S ^a   Niz, David ^a   Smith, Michael ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE MESILATE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; OLANZAPINE; TRIFLUOPERAZINE; ZIPRASIDONE;

ADULT; ARTICLE; CASE REPORT; CHOREOATHETOSIS; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LONG TERM CARE; MALE; MONOTHERAPY; RIGIDITY; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREMOR;

ADULT; ANTIPSYCHOTIC AGENTS; DELUSIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; FOLLOW-UP STUDIES; HALLUCINATIONS; HUMANS; LONG-TERM CARE; MALE; NEUROLOGIC EXAMINATION; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SCHIZOPHRENIA; THIAZOLES;

EID: 11344250222     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Davis R, Markham A. Ziprasidone. CNS Drugs 1997;8:153-9.
2. Tandon R, Harrigan E, Zorn SH. Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J Serot Res 1997;4:159-77.
3. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999;20:491-505.
4. Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001;155(2):128-34.
5. Goff DC, Posever T, Herz L, Simmons J, Kletti N, LaPierre K, et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998;18:296-304.
6. Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998;40:173-84.
7. Guy W, editor. ECDEU assessment manual for psychopharmacology. Washington: US Department of Health, Education and Welfare; 1976. p. 534-7. Publication ADM 76-338.
8. Rosenquist KJ, Walker SS, Ghaemi SN. Tardive dyskinesia and ziprasidone. Am J Psychiatry 2002;159:1436.